GNAO1 as a Novel Predictive Biomarker for Late Relapse in Hepatocellular Carcinoma

Figure 3

The Kaplan–Meier curves of RFS of HCC patients based on GNAO1 expression (low versus high). (a–c) RFS analysis of all HCC patients (n = 316), stages I-II (n = 228), and stages III-IV (n = 70) in the Kaplan–Meier plotter database; (d–e) RFS analysis of all HCC patients (n = 79) and stages I-II (n = 64) based on the IHC results.

(a)

(b)

(c)

(d)

(e)